OBJECTIVE: To investigate the efficacy and safety of Sodium tanshinone ⅡA sulfonate(STS) plus the conventional treatment on acute myocardial infarction(AMI) patients.METHODS: We searched several electrical databases ...OBJECTIVE: To investigate the efficacy and safety of Sodium tanshinone ⅡA sulfonate(STS) plus the conventional treatment on acute myocardial infarction(AMI) patients.METHODS: We searched several electrical databases and hand searched several Chinese medical journals up to January 2019. Randomized controlled trials(RCTs) comparing STS plus conventional treatment with conventional treatment were retrieved.Study screening, data extraction, quality assessment, and data analysis were conducted in accordance with the Cochrane standards.RESULTS: Sixteen trials involving 1383 people were included. The Meta-analysis showed STS combined with conventional treatment was a better treatment option than conventional treatment alone in reducing the risk of mortality, heart failure, arrhythmia and shock. In addition, STS was associated with improvement in left ventricular ejection fraction(LVEF) and left ventricular end diastolic dimension(LVEDD). No significant difference of STS was found on recurrent angina and recurrent AMI. However,the safety of STS remained uncertain for limited data.CONCLUSION: Compared with conventional treatment alone, STS combined with conventional treatment may provide more benefits for patients with AMI. Due to the fact that the overall quality of all included trials is generally low, further large-scale high quality trials are warranted.展开更多
OBJECTIVE: To evaluate the effectiveness of an adjuvant therapy from Traditional Chinese Medicine for supplementing Qi and promoting blood circulation(CMSQPBC) on left ventricular remodeling in patients after myocardi...OBJECTIVE: To evaluate the effectiveness of an adjuvant therapy from Traditional Chinese Medicine for supplementing Qi and promoting blood circulation(CMSQPBC) on left ventricular remodeling in patients after myocardial infarction(MI).METHODS: Randomized controlled trials were identified in the Cochrane Library, Embase, Web of Science, PubMed, China National Knowledge Infrastructure Database, Chinese Biomedical Literature Database, China Science and Technology Journal Database, Wanfang databases, reviews, and reference lists of relevant articles. The weighted mean difference(WMD) was calculated for changes in the left ventricular ejection fraction(LVEF), LV end-diastolic volume(LVEDV) and LV end-systolic volume(LVESV) from baseline to follow-up(> 3 months) by using random-effects Meta-analysis. The primary outcome was change in LVEF, and secondary outcomes were changes in LV dimensions including LVEDV and LVESV.RESULTS: A total of 10 trials(enrolling 854 participants, median follow-up six months) evaluated the association between CMSQPBC and changes in LV function and volume. Compared with the control group, CMSQPBC significantly improved LVEF(854 patients;WMD: 4.97%, 95% CI: 3.78-6.15;P < 0.001)and attenuated the enlargement of LVEDV(607 patients;WMD:-7.89 mL, 95% CI:-11.54 to-4.24;P<0.001) and LVESV(364 patients;WMD =-5.80 mL,95% CI,-9.60 to-2.01;P < 0.01).CONCLUSION: CMSQPBC may reverse deleterious pathological remodeling after myocardial infarction. Higher quality and more rigorous randomized trials with larger sample sizes are needed to further confirm the findings.展开更多
基金Supported by Project of Administration of Traditional Chinese Medicine of Guangdong Province Clinical Study of the Effect of TanshinoneⅡA Sodium Sulfonate on Coronary Microcirculation in Patients with Acute Coronary Syndrome(No. 20181126)Project of Special Clinical Research Fund for TCM Science and Technology of Guangdong Provincial Hospital of Chinese Medicine Clinical Study of the Effect of TanshinoneⅡA Sodium Sulfonate on Coronary Microcirculation in Patients with Acute Coronary Syndrome (No.YN2018QL06)Project of Department of Education of Guangdong Province Acute Myocardial Infarction Chinese Medicine Prevention and Treatment Team (No. 2020KT1207)。
文摘OBJECTIVE: To investigate the efficacy and safety of Sodium tanshinone ⅡA sulfonate(STS) plus the conventional treatment on acute myocardial infarction(AMI) patients.METHODS: We searched several electrical databases and hand searched several Chinese medical journals up to January 2019. Randomized controlled trials(RCTs) comparing STS plus conventional treatment with conventional treatment were retrieved.Study screening, data extraction, quality assessment, and data analysis were conducted in accordance with the Cochrane standards.RESULTS: Sixteen trials involving 1383 people were included. The Meta-analysis showed STS combined with conventional treatment was a better treatment option than conventional treatment alone in reducing the risk of mortality, heart failure, arrhythmia and shock. In addition, STS was associated with improvement in left ventricular ejection fraction(LVEF) and left ventricular end diastolic dimension(LVEDD). No significant difference of STS was found on recurrent angina and recurrent AMI. However,the safety of STS remained uncertain for limited data.CONCLUSION: Compared with conventional treatment alone, STS combined with conventional treatment may provide more benefits for patients with AMI. Due to the fact that the overall quality of all included trials is generally low, further large-scale high quality trials are warranted.
基金Supported by National Science Foundation(No.81703877,81703848)National Basic Research Program of China(973 Program,2015CB554400)。
文摘OBJECTIVE: To evaluate the effectiveness of an adjuvant therapy from Traditional Chinese Medicine for supplementing Qi and promoting blood circulation(CMSQPBC) on left ventricular remodeling in patients after myocardial infarction(MI).METHODS: Randomized controlled trials were identified in the Cochrane Library, Embase, Web of Science, PubMed, China National Knowledge Infrastructure Database, Chinese Biomedical Literature Database, China Science and Technology Journal Database, Wanfang databases, reviews, and reference lists of relevant articles. The weighted mean difference(WMD) was calculated for changes in the left ventricular ejection fraction(LVEF), LV end-diastolic volume(LVEDV) and LV end-systolic volume(LVESV) from baseline to follow-up(> 3 months) by using random-effects Meta-analysis. The primary outcome was change in LVEF, and secondary outcomes were changes in LV dimensions including LVEDV and LVESV.RESULTS: A total of 10 trials(enrolling 854 participants, median follow-up six months) evaluated the association between CMSQPBC and changes in LV function and volume. Compared with the control group, CMSQPBC significantly improved LVEF(854 patients;WMD: 4.97%, 95% CI: 3.78-6.15;P < 0.001)and attenuated the enlargement of LVEDV(607 patients;WMD:-7.89 mL, 95% CI:-11.54 to-4.24;P<0.001) and LVESV(364 patients;WMD =-5.80 mL,95% CI,-9.60 to-2.01;P < 0.01).CONCLUSION: CMSQPBC may reverse deleterious pathological remodeling after myocardial infarction. Higher quality and more rigorous randomized trials with larger sample sizes are needed to further confirm the findings.
